Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HUM Stock Forecast 2026-2027
$276.59
Current Price
$33.27B
Market Cap
Buy 9
Hold 17
Sell 1
Wall St Analyst Ratings
Distance to HUM Price Targets
+27.6%
To High Target of $353.00
+3.9%
To Median Target of $287.50
-22.3%
To Low Target of $215.00
HUM Price Momentum
-1.2%
1 Week Change
+3.0%
1 Month Change
-3.7%
1 Year Change
+8.0%
Year-to-Date Change
-12.3%
From 52W High of $315.35
+33.7%
From 52W Low of $206.87
📊 TOP ANALYST CALLS
Did HUM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Humana is one of their latest high-conviction picks.
Latest HUM Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, HUM has a neutral consensus with a median price target of $287.50 (ranging from $215.00 to $353.00). The overall analyst rating is Buy (7.0/10). Currently trading at $276.59, the median forecast implies a 3.9% upside. This outlook is supported by 9 Buy, 17 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Frank Morgan at RBC Capital, projecting a 27.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HUM Analyst Ratings
9
Buy
17
Hold
1
Sell
HUM Price Target Range
Low
$215.00
Average
$287.50
High
$353.00
Current: $276.59
Latest HUM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HUM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 7, 2026 | Wells Fargo | Stephen Baxter | Equal-Weight | Downgrade | $290.00 |
| Jan 5, 2026 | Barclays | Andrew Mok | Equal-Weight | Maintains | $245.00 |
| Dec 18, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $262.00 |
| Dec 5, 2025 | Jefferies | David Windley | Buy | Upgrade | $313.00 |
| Nov 25, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $234.00 |
| Nov 10, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $285.00 |
| Nov 7, 2025 | Deutsche Bank | Hold | Maintains | $N/A | |
| Oct 10, 2025 | B of A Securities | Kevin Fischbeck | Neutral | Maintains | $300.00 |
| Oct 9, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $345.00 |
| Oct 7, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $347.00 |
| Oct 3, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $245.00 |
| Oct 3, 2025 | Guggenheim | Jason Cassorla | Buy | Reiterates | $N/A |
| Sep 22, 2025 | Evercore ISI Group | Elizabeth Suzuki | In-Line | Initiates | $295.00 |
| Sep 5, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $315.00 |
| Sep 5, 2025 | Bernstein | Lance Wilkes | Outperform | Maintains | $341.00 |
| Sep 2, 2025 | B of A Securities | Kevin Fischbeck | Neutral | Maintains | $312.00 |
| Aug 21, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $322.00 |
| Aug 14, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $344.00 |
| Aug 14, 2025 | Argus Research | David Toung | Hold | Reiterates | $281.99 |
| Jul 31, 2025 | Piper Sandler | Jessica Tassan | Neutral | Maintains | $272.00 |
Humana Inc. (HUM) Competitors
The following stocks are similar to Humana based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Humana Inc. (HUM) Financial Data
Humana Inc. has a market capitalization of $33.27B with a P/E ratio of 25.9x. The company generates $126.36B in trailing twelve-month revenue with a 1.0% profit margin.
Revenue growth is +11.1% quarter-over-quarter, while maintaining an operating margin of +2.0% and return on equity of +7.2%.
Valuation Metrics
Market Cap
$33.27B
Enterprise Value
$24.15B
P/E Ratio
25.9x
PEG Ratio
-0.4x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
+11.1%
Gross Margin
N/A
Operating Margin
+2.0%
Net Margin
+1.0%
EPS Growth
-59.4%
Financial Health
Cash/Price Ratio
+66.5%
Current Ratio
2.0x
Debt/Equity
69.7x
ROE
+7.2%
ROA
+4.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Humana Inc. (HUM) Business Model
About Humana Inc.
What They Do
Provides comprehensive health insurance products and services.
Business Model
Humana Inc. generates revenue primarily through the sale of health insurance products, focusing on Medicare Advantage plans for seniors, as well as individual and group medical plans. The company also offers specialty products such as dental and vision care, catering to both individual consumers and large organizations.
Additional Information
Based in Louisville, Kentucky, Humana is a key player in the U.S. healthcare system, emphasizing wellness and preventive care. The company is committed to improving health outcomes through enhanced digital solutions and strategic partnerships aimed at promoting integrated care between medical professionals and insurers.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
65,680
CEO
Mr. James A. Rechtin M.B.A.
Country
United States
IPO Year
1981
Website
www.humana.comHumana Inc. (HUM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
UnitedHealth Sinks 34.5% in a Year: Buy the Dip Before Q4 Earnings?
UNH shares are down 34.5% in a year as costs and margins bite, with Q4 earnings and 2026 guidance set to test whether value is emerging.
Jan 05, 2026
By Kaibalya Pravo Dey
Analyst Blog
Latest News
Quick Summary
CenterWell Pharmacy launches a new program to dispense obesity management medications, targeting employers to enhance employee health benefits.
Why It Matters
CenterWell Pharmacy's new obesity management program may boost demand for obesity medications, impacting pharmaceutical sales and healthcare costs, influencing investor sentiment in healthcare sectors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Humana Inc. (NYSE: HUM) will release its 4Q25 financial results on February 11, 2026, at 6:00 a.m. ET, followed by a Q&A session at 8:00 a.m. ET. Details will be available on their Investor Relations page.
Why It Matters
Humana's upcoming earnings release and Q&A session will provide insights into its financial health and future guidance, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
HUM faces near-term challenges due to Medicare Advantage pressures but shows resilience compared to peers, suggesting investors should remain patient.
Why It Matters
HUM faces Medicare Advantage challenges impacting short-term growth, but its relative stability suggests potential for long-term value, signaling a cautious investment outlook.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Zacks Premium research service offers Zacks Style Scores to help investors identify strong stocks, catering to value, growth, and momentum strategies.
Why It Matters
Zacks Style Scores enhance stock selection across investment strategies, potentially improving returns and aiding in portfolio management for various investor types.
Source: Zacks Investment Research
Market Sentiment:
Positive
Fitch downgrades Humana's credit ratings
29 days ago
Quick Summary
Fitch downgraded the credit ratings of Humana and its subsidiaries on Monday, indicating a negative shift in the company's creditworthiness.
Why It Matters
Fitch's downgrade of Humana's credit ratings signals increased risk for investors, potentially leading to higher borrowing costs and reduced confidence in the company's financial stability.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
The U.S. Defense Department awarded Humana a $7.3 billion contract for health care and administrative support services.
Why It Matters
The $7.3 billion deal for Humana boosts its revenue prospects, signals strong government spending in healthcare, and may positively impact stock performance and investor confidence.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About HUM Stock
What is Humana Inc.'s (HUM) stock forecast for 2026?
Based on our analysis of 39 Wall Street analysts, Humana Inc. (HUM) has a median price target of $287.50. The highest price target is $353.00 and the lowest is $215.00.
Is HUM stock a good investment in 2026?
According to current analyst ratings, HUM has 9 Buy ratings, 17 Hold ratings, and 1 Sell ratings. The stock is currently trading at $276.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HUM stock?
Wall Street analysts predict HUM stock could reach $287.50 in the next 12 months. This represents a 3.9% increase from the current price of $276.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Humana Inc.'s business model?
Humana Inc. generates revenue primarily through the sale of health insurance products, focusing on Medicare Advantage plans for seniors, as well as individual and group medical plans. The company also offers specialty products such as dental and vision care, catering to both individual consumers and large organizations.
What is the highest forecasted price for HUM Humana Inc.?
The highest price target for HUM is $353.00 from Frank Morgan at RBC Capital, which represents a 27.6% increase from the current price of $276.59.
What is the lowest forecasted price for HUM Humana Inc.?
The lowest price target for HUM is $215.00 from at , which represents a -22.3% decrease from the current price of $276.59.
What is the overall HUM consensus from analysts for Humana Inc.?
The overall analyst consensus for HUM is neutral. Out of 39 Wall Street analysts, 9 rate it as Buy, 17 as Hold, and 1 as Sell, with a median price target of $287.50.
How accurate are HUM stock price projections?
Stock price projections, including those for Humana Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 4:18 PM UTC